Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Preajmaline-induced cholestatic hepatitis].

E Pras1, S Steinlauf, Y Sidi

  • 1Dept. of Medicine D, Beilinson Medical Center, Petah Tikva.

Harefuah
|November 15, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prophylactic colchicine for familial Mediterranean fever: response rates revisited.

Scandinavian journal of rheumatology·2025
Same author

Behavior of biometric parameters during clinical hours.

Journal francais d'ophtalmologie·2024
Same author

Hepatic Iron Overload following Liver Transplantation from a C282Y/H63D Compound Heterozygous Donor.

Case reports in hepatology·2018
Same author

Fractures after multimodality treatment of soft tissue sarcomas with isolated limb perfusion and radiation; likely to occur and hard to heal.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2018
Same author

Mutations in AIFM1 cause an X-linked childhood cerebellar ataxia partially responsive to riboflavin.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2017
Same author

Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes.

Oncogene·2017
Same journal

[Tennis Elbow Among Players].

Harefuah·2026
Same journal

[Internal Medicine - My Mission].

Harefuah·2026
Same journal

[Treatment of Morbid Obesity in Israel: GLP-1 Agonists Versus Bariatric Surgery - Clinical and Economic Aspects].

Harefuah·2026
Same journal

[Baby steps: Post-operative Treatment Recommendations for Pediatric Tracheostomy in Israel].

Harefuah·2026
Same journal

[Mastoiditis Caused by Fusobacterium Necrophorum: an Unusual Pathogen in a Well-Known Disease].

Harefuah·2026
Same journal

[Cochlear Implantation in Single-Sided Deafness - Six Years of Follow-Up from Diagnosis and Consistent Use, Through Dedicated and Creative Auditory Learning, to the Development of Bilateral Central Processing Abilities].

Harefuah·2026
See all related articles

Preajmaline can cause cholestatic hepatitis, a liver condition. Fortunately, symptoms typically resolve when the medication is discontinued, as seen in two patient cases.

Area of Science:

  • Hepatology
  • Clinical Pharmacology
  • Toxicology

Background:

  • Cholestatic hepatitis is a liver disease characterized by impaired bile flow.
  • Drug-induced liver injury (DILI) is a significant concern in clinical practice.
  • Preajmaline is an antiarrhythmic drug with potential hepatotoxic effects.

Observation:

  • Two cases of cholestatic hepatitis associated with preajmaline use are presented.
  • One patient was a 40-year-old woman, and the other a 74-year-old man.
  • The male patient experienced jaundice lasting for eight months.

Findings:

  • Complete recovery from preajmaline-induced hepatitis was observed in both presented cases upon drug cessation.
  • Literature review indicates approximately 40 reported cases of preajmaline-induced hepatitis.

Related Experiment Videos

  • Most patients recover, but one case progressed to biliary cirrhosis when co-administered with other hepatotoxic agents.

    • Implications:

    • Discontinuation of preajmaline is crucial for managing drug-induced cholestatic hepatitis.
    • Healthcare providers should be vigilant for potential liver injury in patients using preajmaline.
    • Further research into the mechanisms of preajmaline hepatotoxicity may inform safer prescribing practices.